Radiation levels outside a patient undergoing 177Lu-PSMA radioligand therapy

被引:0
|
作者
Li, Huan [1 ]
Liu, Haikuan [1 ]
Zhang, Weiyuan [1 ]
Lin, Xin [1 ]
Li, Zhiling [1 ]
Zhuo, Weihai [1 ]
机构
[1] Fudan Univ, Inst Radiat Med, Shanghai 200032, Peoples R China
基金
中国国家自然科学基金;
关键词
Lu-177-PSMA; radioligand therapy; extracorporeal radiation level; Monte Carlo simulation; PROSTATE-CANCER; SAFETY;
D O I
10.1088/1361-6498/ad3835
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Understanding the spatial distribution of radiation levels outside of a patient undergoing Lu-177 radioligand therapy is not only helpful for conducting correct tests for patient release, but also useful for estimation of its potential exposure to healthcare workers, caregivers, family members, and the general public. In this study, by mimicking the Lu-177-labeled prostate-specific membrane antigen radioligand therapy for prostate cancers in an adult male, the spatial distribution of radiation levels outside of the phantom was simulated based on the Monte Carlo software of Particle and Heavy Ion Transport System, and verified by a series of measurements. Moreover, the normalized dose rates were further formulized on the three transverse planes representing the heights of pelvis, abdomen and chest. The results showed that the distributions of radiation levels were quite complex. Multi-directional and multi-height measurements are needed to ensure the external dose rate to meet the release criteria. In general, the radiation level was higher at the horizontal plane where the source was located, and the levels in front and behind of the body were higher than those of the left and right sides at the same height. The ratio of simulated dose rates to measured ones ranged from 0.82 to 1.19 within 1 m away from the body surface in all directions. Based on the established functions, the relative root mean square deviation between the calculated and simulated values were 0.21, 0.25 and 0.23 within a radius of 1 m on the pelvis, abdomen and chest transverse planes, respectively. It is expected that the results of this study would be helpful for guiding the test of extracorporeal radiation to determine the patient's release, and of benefit to estimate the radiation exposure to others.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] 177Lu-PSMA Radioligand Therapy for Prostate Cancer
    Fendler, Wolfgang P.
    Rahbar, Kambiz
    Herrmann, Ken
    Kratochwil, Clemens
    Eiber, Matthias
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58 (08) : 1196 - 1200
  • [2] Long-Term Nephrotoxicity of 177Lu-PSMA Radioligand Therapy
    Steinhelfer, Lisa
    Lunger, Lukas
    Cala, Lisena
    Pfob, Christian H.
    Lapa, Constantin
    Hartrampf, Philipp E.
    Buck, Andreas K.
    Schaefer, Hannah
    Schmaderer, Christoph
    Tauber, Robert
    Brosch-Lenz, Julia
    Haller, Bernhard
    Meissner, Valentin H.
    Knorr, Karina
    Weber, Wolfgang A.
    Eiber, Matthias
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (01) : 79 - 84
  • [3] PSMA-Negative Lesion Progression Under 177Lu-PSMA Radioligand Therapy
    Murthy, Vishnu
    Allen-Auerbach, Martin
    Lam, Richard
    Owen, Dawn
    Czernin, Johannes
    Calais, Jeremie
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (09) : 1502 - 1503
  • [4] Optimisation of the Radiation Dosimetry Protocol in 177Lu-PSMA Therapy
    Mink, M.
    Peters, S. M.
    Prive, B. M.
    de Bakker, M.
    Muselaers, C. H.
    Mehra, N.
    Witjes, J. A.
    Gotthardt, M.
    Timmermans, C. W.
    Nagarajah, J.
    Konijnenberg, M. W.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (SUPPL 1) : S73 - S73
  • [5] Radionuclide Therapy With 177Lu-PSMA in a Patient With Hepatocellular Carcinoma
    Pretet, Valentin
    Giraudet, Anne Laure
    Vergnaud, Laure
    Paquet, Emilie
    Kryza, David
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (06) : 584 - 586
  • [6] Baseline PSMA PET/CT as a predictive biomarker for toxicity and patient-reported outcomes in mCRPC patients undergoing 177Lu-PSMA radioligand therapy
    Murthy, Vishnu
    Lokre, Ojaswita
    Perk, Timothy G.
    Chen, Lucia
    Thin, Pan
    Nguyen, Kathleen
    Lira, Stephanie
    Alano, Rejah M.
    Gafita, Andrei
    Czernin, Johannes
    Calais, Jeremie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] Assessing Response to 177Lu-PSMA Radioligand Therapy Using Modified PSMA PET Progression Criteria
    Michalski, Kerstin
    Klein, Claudius
    Brueggemann, Tonio
    Meyer, Philipp T.
    Jilg, Cordula Annette
    Ruf, Juri
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (12) : 1741 - 1746
  • [8] Pre- or Post-Chemotherapy: Effect of 177Lu-PSMA Radioligand Therapy on PSMA Expression
    Yadav, Surekha
    Heath, Courtney Lawhn
    Juarez, Roxanna
    De Kouchkovsky, Ivan
    Aggarwal, Rahul
    Hope, Thomas
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [9] Baseline PSMA PET/CT as a Predictive Biomarker for Hematologic Toxicity and Patient-Reported Outcomes in mCRPC Patients Undergoing 177Lu-PSMA Radioligand Therapy
    Murthy, Vishnu
    Lokre, Ojaswita
    Perk, Timothy
    Chen, Lucia
    Thin, Pan
    Nguyen, Kathleen
    Lira, Stephanie
    Alano, Rejah
    Gafita, Andrei
    Czernin, Johannes
    Calais, Jeremie
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [10] Dosimetry of 177Lu-PSMA
    Serrano, B.
    Amblard, R.
    Koulibaly, P. M.
    Gasteuil, J.
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2023, 47 (06): : 323 - 332